Matches in SemOpenAlex for { <https://semopenalex.org/work/W4234638657> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4234638657 abstract "Abstract Background: Sequential inhibition of the vascular endothelial growth factor (VEGF) pathway with sorafenib could be useful for patients with metastatic renal cell carcinoma (RCC). Our aim was to determine the activity and tolerability of sorafenib as a second-line therapy in advanced RCC initially treated with a different VEGF-tyrosine kinase inhibitor (TKI). Methods: A prospective observational cohort in Mexico (2012–2019). We included 132 subjects with metastatic RCC and who had progression despite treatment with sunitinib. The primary end-point was time to disease progression as evaluated every 12–16 weeks. Results: The mean age of the cohort was 59 years (interquartile range [IQR] 50-72), 96 (73%) were men, and 48 (36%) had a favorable prognosis according to the IMDC (International Metastatic RCC Database Consortium) prognostic model. The median progression-free survival (PFS) and overall-survival after the introduction of sorafenib treatment was 8.6 months (95% confidence interval [CI]: 6.7–10.5) and 40 months (95% CI: 34.5–45.4) respectively. The median overall survival from RCC diagnosis to death was 71 months (95% CI: 58.2–83.8). On multivariable analyses, age >65 years was associated with a longer PFS (HR 0.51; 95% CI: 0.31-0.86; p = 0.018). The median PFS in subjects aged >65 years was longer compared to subjects ≤65 years (14.0 [95% CI: 9.2–18.8] vs . 7.2 months [95% CI: 5.3–9.1]; p = 0.012). Adverse events grade ≥3 associated with sorafenib occurred in 38 (29%) patients. Conclusion: Sequential inhibition of VEGF with sorafenib as a second-line treatment may benefit patients with metastatic RCC, especially in subjects >65 years old." @default.
- W4234638657 created "2022-05-12" @default.
- W4234638657 creator A5035165484 @default.
- W4234638657 creator A5063992570 @default.
- W4234638657 creator A5071994251 @default.
- W4234638657 date "2021-01-04" @default.
- W4234638657 modified "2023-10-14" @default.
- W4234638657 title "Sorafenib as a Second-Line Treatment in Metastatic Renal Cell Carcinoma in Mexico: A Prospective Cohort Study" @default.
- W4234638657 doi "https://doi.org/10.21203/rs.3.rs-51070/v3" @default.
- W4234638657 hasPublicationYear "2021" @default.
- W4234638657 type Work @default.
- W4234638657 citedByCount "0" @default.
- W4234638657 crossrefType "posted-content" @default.
- W4234638657 hasAuthorship W4234638657A5035165484 @default.
- W4234638657 hasAuthorship W4234638657A5063992570 @default.
- W4234638657 hasAuthorship W4234638657A5071994251 @default.
- W4234638657 hasBestOaLocation W42346386571 @default.
- W4234638657 hasConcept C119060515 @default.
- W4234638657 hasConcept C126322002 @default.
- W4234638657 hasConcept C141071460 @default.
- W4234638657 hasConcept C143998085 @default.
- W4234638657 hasConcept C188816634 @default.
- W4234638657 hasConcept C197934379 @default.
- W4234638657 hasConcept C203092338 @default.
- W4234638657 hasConcept C2777472916 @default.
- W4234638657 hasConcept C2778019345 @default.
- W4234638657 hasConcept C2778375690 @default.
- W4234638657 hasConcept C2778439243 @default.
- W4234638657 hasConcept C2778695046 @default.
- W4234638657 hasConcept C2779490328 @default.
- W4234638657 hasConcept C2780739268 @default.
- W4234638657 hasConcept C3019894029 @default.
- W4234638657 hasConcept C535046627 @default.
- W4234638657 hasConcept C71924100 @default.
- W4234638657 hasConcept C72563966 @default.
- W4234638657 hasConceptScore W4234638657C119060515 @default.
- W4234638657 hasConceptScore W4234638657C126322002 @default.
- W4234638657 hasConceptScore W4234638657C141071460 @default.
- W4234638657 hasConceptScore W4234638657C143998085 @default.
- W4234638657 hasConceptScore W4234638657C188816634 @default.
- W4234638657 hasConceptScore W4234638657C197934379 @default.
- W4234638657 hasConceptScore W4234638657C203092338 @default.
- W4234638657 hasConceptScore W4234638657C2777472916 @default.
- W4234638657 hasConceptScore W4234638657C2778019345 @default.
- W4234638657 hasConceptScore W4234638657C2778375690 @default.
- W4234638657 hasConceptScore W4234638657C2778439243 @default.
- W4234638657 hasConceptScore W4234638657C2778695046 @default.
- W4234638657 hasConceptScore W4234638657C2779490328 @default.
- W4234638657 hasConceptScore W4234638657C2780739268 @default.
- W4234638657 hasConceptScore W4234638657C3019894029 @default.
- W4234638657 hasConceptScore W4234638657C535046627 @default.
- W4234638657 hasConceptScore W4234638657C71924100 @default.
- W4234638657 hasConceptScore W4234638657C72563966 @default.
- W4234638657 hasLocation W42346386571 @default.
- W4234638657 hasLocation W42346386572 @default.
- W4234638657 hasLocation W42346386573 @default.
- W4234638657 hasLocation W42346386574 @default.
- W4234638657 hasOpenAccess W4234638657 @default.
- W4234638657 hasPrimaryLocation W42346386571 @default.
- W4234638657 hasRelatedWork W2020852956 @default.
- W4234638657 hasRelatedWork W2056454490 @default.
- W4234638657 hasRelatedWork W2075281345 @default.
- W4234638657 hasRelatedWork W2119565846 @default.
- W4234638657 hasRelatedWork W2152442982 @default.
- W4234638657 hasRelatedWork W2154171266 @default.
- W4234638657 hasRelatedWork W2590331747 @default.
- W4234638657 hasRelatedWork W2792950327 @default.
- W4234638657 hasRelatedWork W2894779831 @default.
- W4234638657 hasRelatedWork W2908181257 @default.
- W4234638657 isParatext "false" @default.
- W4234638657 isRetracted "false" @default.
- W4234638657 workType "article" @default.